赛隆药业集团股份有限公司 2023 年度监事会工作报告 2023 年，公司监事会依照《公司法》、《证券法》、《深圳证券交易所股票上市 规则》、《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运 作》等法律法规及《公司章程》、《监事会议事规则》等相关规定，本着恪尽职守、 勤勉尽责的工作态度履行法律、法规赋予的各项职权和义务，积极出席或列席相 关会议，督促董事、高级管理人员合法合规履行职责，促进公司规范运作和健康 持续发展。现将 2023 年度工作情况报告如下： 一、监事会会议召开情况 （一）报告期内，公司监事会共召开五次监事会会议，具体情况如下： 1．第三届监事会第八次会议 会议于 2023 年 10 月 24 日召开，3 名监事全部出席会议，审议通过了《关 于公司 2023 年第三季度报告的议案》、《关于向银行申请授信并由实际控制人提 供担保的议案》、议《关于向关联方出售部分房产的议案》。 （二）报告期内，监事会列席了公司 2022 年度股东大会、2023 年第一次临 时股东大会、2023 年第二次临时股东大会、2023 年第三次临时股东大会、第三 届董事会第十一次会议、第三届董事会第十二次 ...

证券代码：002898 证券简称：赛隆药业 公告编号：2024-034 赛隆药业集团股份有限公司（以下简称"公司"）根据《企业会计准 则》、《深圳证券交易所股票上市规则》、《深圳证券交易所上市公司自律监 管指南第1号——业务办理》及公司会计政策的相关规定，对截至2023年12月31 日合并报表范围内应收账款、其他应收款和存货计提减值准备3,947,714.07 元，占2023年度经审计归属于母公司所有者净利润的41.41%，现将具体情况公 告如下： 一、本次计提减值准备情况概述 1.本次计提减值准备的原因 为公允、客观地反映公司财务状况、资产价值及经营成果，根据《企业会 计准则》、证监会及公司会计政策的相关规定，公司对截至2023年12月31日合 并报表范围内的应收票据、应收账款、其他应收款、合同资产、存货、固定资 产、无形资产等资产进行了全面清查，认为上述资产中的部分资产存在一定的 减值迹象，公司本着谨慎性原则，对可能发生减值损失的相关资产计提资产减 值准备、信用减值准备。 2.本次计提减值准备的资产范围、总金额和计入的报告期间 公司2023年度有迹象可能发生减值的资产为应收账款、其他应收款和存 货，经减值 ...

赛隆药业集团股份有限公司 独立董事专门会议制度 第一条 为了进一步规范赛隆药业集团股份有限公司（以下简称"公司"） 独立董事专门会议的议事方式和决策程序，促使并保障独立董事有效地履行其职 责。根据 中华人民共和国公司法》、 上市公司独立董事管理办法》、 深圳证券 交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等有关法律、 法规、规范性文件和 赛隆药业集团股份有限公司章程》（以下简称 " 公司章程》"）、 赛隆药业集团股份有限公司独立董事工作制度》（以下简称 " 独立董事工作制 度》"）的有关规定，制定本制度。 第二条 独立董事专门会议是指全部由独立董事参加的专门会议。独立董事 专门会议对所议事项进行独立研讨，从公司和中小股东利益角度进行思考判断， 并且形成讨论意见。 第三条 公司独立董事定期或者不定期召开独立董事专门会议，并于会议召 开前三天通知全体独立董事并提供相关资料和信息。情况紧急，需要尽快召开专 门会议的，经全体独立董事一致同意，可以随时通过电话或者其他口头方式发出 会议通知，通知时限可不受本条款限制。 第七条 独立董事专门会议的表决，实行一人一票。表决方式应当采取记名 投票表决方式。 ...

赛隆药业集团股份有限公司 （陈小辛） 现将本人2023年度履职情况报告如下： 一、独立性情况 报告期内，本人任职符合《上市公司独立董事管理办法》、《深圳证券交易 所上市公司自律监管指引第1号——主板上市公司规范运作》等有关独立董事独 立性要求，不存在影响独立性的情况。 二、年度履职情况 2023 年度独立董事述职报告 （一）出席董事会、股东大会情况 2023 年度，公司共召开了 6 次董事会会议，本人出席了全部会议，对所有 审议事项均进行了表决，并对董事会决议进行了签署，没有委托出席和缺席会议 的情况。 2023 年度，公司共召开了 4 次股东大会，本人出席了全部会议。 本人作为赛隆药业集团股份有限公司（以下简称"公司"）独立董事，在2023 年度严格按照《公司法》、《上市公司独立董事管理办法》、《深圳证券交易所 上市公司自律监管指引第1号——主板上市公司规范运作》等相关规定，发挥自 己的专业优势，积极关注和参与研究公司的发展，客观、公正、独立地履行职责， 充分发挥独立董事作用，维护公司整体利益和全体股东特别是中小股东的合法权 益。 （二）参与董事会专门委员会、独立董事专门会议工作情况 报告期内，本人出席董事 ...

证券代码：002898 证券简称：赛隆药业 公告编号：2024-032 特别提示： (1)截止本公告日，公司对全资子公司担保额度为16,000万元，对参股子公 司担保额度为24,500万元，合计担保总额为40,500万元，占公司2023年度经审 计净资产的比例为75.58%；截止本公告日，公司对全资子公司实际担保金额为 6,749.87万元，对参股子公司实际担保金额为24,500万元，合计实际担保金额 为31,249.87万元，占公司2023年度经审计净资产的比例为58.31%。除上述担保 外，公司及子公司无其他担保事项，也不存在逾期担保、涉及诉讼担保的情 况。 (2)全资子公司湖南赛隆药业（长沙）有限公司资产负债率超过70%，拟提 供的担保额度为2,000万元，敬请广大投资者注意防范风险。 一、交易及担保情况概述 赛隆药业集团股份有限公司（以下简称"公司"）2024年4月18日召开第四 届董事会第二次会议，审议通过了《关于全资子公司开展融资租赁业务并为其 提供担保的议案》，具体情况如下： 为优化融资结构，满足业务发展需要，公司全资子公司湖南赛隆药业（长 沙）有限公司(以下简称"长沙赛隆")拟与横琴华通金融租 ...

证券代码：002898 证券简称：赛隆药业 公告编号：2024-029 赛隆药业集团股份有限公司 关于 2023 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 赛隆药业集团股份有限公司（以下简称"公司"）于2024年4月18日召开了第 四届董事会第二次会议，审议通过了《关于2023年度利润分配预案的议案》，并 将该议案提交公司2023年度股东大会审议。现将该分配预案的基本情况公告如下： 一、2023年度利润分配预案情况 1.公司2023年度可分配利润情况 根据致同会计师事务所（特殊普通合伙）审计，公司2023年度合并报表实现 归属于母公司所有者的净利润为9,533,684.57元，未分配利润为53,402,564.10 元。2023年度母公司实现净利润85,056,171.92元，加上年初未分配利润 -75,726,870.64元，提取法定盈余公积932,930.13元，截至2023年12月31日，实 际可供母公司所有者分配的利润为8,396,371.15元。 2.公司2023年度利润分配预案主要内容 公司2023年度利润分配预案如下 ...

Financial Performance - The company's operating revenue for 2023 reached ¥310,627,026.68, representing a year-over-year increase of 17.58% compared to ¥264,192,655.91 in 2022[20]. - The net profit attributable to shareholders of the listed company was ¥9,533,684.57, a significant increase of 125.55% from ¥37,312,348.4 in the previous year[20]. - The net cash flow from operating activities was ¥35,706,967.4, showing a substantial increase of 152.80% compared to ¥14,124,685.7 in 2022[20]. - The basic and diluted earnings per share for 2023 were both ¥0.0542, a turnaround from a loss of ¥0.2120 in 2022, marking a 125.57% improvement[20]. - The total assets at the end of 2023 were ¥813,843,574, reflecting a decrease of 4.03% from ¥847,991,091 at the end of 2022[21]. - The net assets attributable to shareholders of the listed company increased by 1.81% to ¥535,881,684 compared to ¥526,348,692 in 2022[21]. - The company reported a significant reduction in non-recurring gains and losses, with a net profit excluding non-recurring items of -¥2,435,899.67 in 2023 compared to ¥54,468,952.7 in 2022, a decrease of 95.53%[20]. - The company achieved operating revenue of RMB 310,627,026.68, representing a year-on-year growth of 17.58%[45]. - The net profit attributable to the parent company was RMB 9,533,684.57, reflecting a significant increase of 125.55% compared to the previous year[45]. - The company reported a total revenue of 9.919 billion in the fiscal year 2023, maintaining a stable performance compared to the previous year[111]. - The company reported a total revenue of 562.55 million for the fiscal year 2023[127]. Dividend Distribution - The company plans to distribute a cash dividend of 0.20 RMB per 10 shares to all shareholders, based on a total of 176 million shares[4]. - The total distributable profit for the company is RMB 8,396,371.15, with the cash dividend accounting for 100% of the profit distribution[140]. - The cash dividend distribution is based on the latest share capital of 176,000,000 shares[142]. - There were no adjustments to the cash dividend policy during the reporting period, and the policy remains compliant with relevant regulations[140]. Risks and Challenges - The company acknowledges potential risks including industry policy changes, product price reductions, and new drug development risks[4]. - The pharmaceutical industry in China faced challenges in 2023, with the added value of large-scale pharmaceutical industry decreasing by 5.2% year-on-year, and total revenue dropping by 4% to CNY 29,552.5 billion[33]. - The profit of large-scale pharmaceutical enterprises fell by 16.2% year-on-year, marking the first negative growth across key industry metrics in many years[33]. - The average price reduction for the eighth and ninth batches of national centralized procurement was 56% and 58%, respectively, indicating a significant impact on pricing strategies in the industry[35]. - The company recognizes risks related to industry policy changes, product pricing pressures, and new drug development challenges, and will adapt strategies accordingly[85]. - The company faces potential risks regarding the renewal of drug registration certificates and related qualifications, which could adversely affect future development and operations[87]. Research and Development - The company continues to operate a modern pharmaceutical enterprise with a full industry chain, including R&D, production, marketing, and technical services, focusing on various therapeutic areas such as cardiovascular, neurological, and digestive systems[38]. - The company has established a pharmaceutical R&D center with a team experienced in innovation, supporting the development from market research to registration[39]. - The company emphasizes self-initiated R&D while also engaging in collaborative development to enhance its product offerings and meet market demands[39]. - The company aims to continuously develop new drugs based on market needs, leveraging its established R&D capabilities[39]. - Research and development (R&D) investment increased by 51.55% to ¥42,641,319.22 in 2023, up from ¥28,136,219.86 in 2022, representing 13.73% of total revenue[65]. - The number of R&D personnel rose to 81 in 2023, a 3.85% increase from 78 in 2022, with a notable increase in master's degree holders by 37.50%[64]. - The company is actively developing new products, including Lansoprazole and its formulations, with ongoing clinical trials and expected positive impacts on future performance[63]. - The company is focusing on expanding its product line and enhancing its market presence through strategic research and development initiatives[63]. Corporate Governance - The company has a governance structure that complies with relevant laws and regulations, ensuring the protection of shareholders' rights, particularly for minority shareholders[92]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal requirements and effective decision-making[95]. - The company has established an internal audit system to supervise and evaluate internal control activities, effectively managing risks[100]. - The company maintains independence from its controlling shareholder in terms of assets, personnel, finance, and operations, ensuring a complete business system[102]. - The company has established independent financial accounting departments and a complete financial management system, ensuring no interference from controlling shareholders in financial decisions[105]. - The company has a robust internal governance structure, including a board of directors and supervisory board, to enhance management and oversight functions[106]. - The company has established a comprehensive internal control system covering sales, procurement, finance, and human resources, ensuring orderly management and compliance[144]. - The company has established a long-term profit distribution policy that balances sustainable development with reasonable returns for shareholders, particularly small and medium-sized investors[163]. Environmental Compliance - The company has complied with environmental protection laws and regulations, establishing a comprehensive environmental management system[152]. - The company obtained pollution discharge permits for its subsidiaries, with valid periods extending until 2028 and 2027 respectively[153]. - The company has implemented environmental impact assessments for all construction projects, ensuring compliance with relevant regulations[153]. - The company reported a significant focus on environmental protection, implementing effective control measures for pollutants and ensuring compliance with national environmental regulations[157]. - The wastewater treatment facility is equipped with automatic monitoring devices that check COD, ammonia nitrogen, pH, and flow every 2 hours, with abnormal data triggering automatic alerts[158]. Market Expansion and Strategy - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[114]. - The company is actively pursuing market expansion strategies to enhance its competitive position in the pharmaceutical industry[123]. - The company is planning to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[171]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share within the next two years[179]. - A new partnership with a leading healthcare provider is expected to enhance distribution channels and increase sales by 12% over the next year[172]. Operational Efficiency - The company is focusing on reducing operational costs by 15% through efficiency improvements and technology upgrades[171]. - The production system will focus on increasing automation to enhance efficiency and ensure compliance with quality standards, while maintaining stable production of raw materials[84]. - The company plans to strengthen process control and internal management to ensure the effective execution of its annual work plan[84]. Compliance and Legal Matters - The company did not experience any penalties or rectification issues during the reporting period[183]. - There were no significant lawsuits or arbitration matters during the reporting period[182]. - The company has no reported non-operating fund occupation by major shareholders during the reporting period[175]. - The company did not engage in any asset or equity acquisitions or sales during the reporting period[185].

Financial Performance - The company's revenue for Q1 2024 was ¥69,484,400.80, a decrease of 12.52% compared to ¥79,427,813.05 in the same period last year[5] - Net profit attributable to shareholders was ¥1,624,090.66, down 49.21% from ¥3,197,374.56 year-on-year[5] - Basic and diluted earnings per share were both ¥0.0092, a decrease of 49.45% from ¥0.0182 in the same period last year[5] - Net profit for the current period is ¥1,624,090.66, down 49.2% from ¥3,197,374.56 in the previous period[18] - Total operating revenue for the current period is ¥69,484,400.80, a decrease of 12.4% from ¥79,427,813.05 in the previous period[17] - Total operating costs decreased to ¥66,306,449.91 from ¥78,468,996.00, reflecting a reduction of 15.5%[17] - Sales revenue from goods and services received cash of ¥33,345,291.71, down 50.2% from ¥67,006,626.11 in the previous period[19] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥17,436,292.79, representing a decline of 214.04% compared to -¥5,552,217.03 in the previous year[5] - Cash flow from operating activities shows a net outflow of ¥17,436,292.79, compared to a smaller outflow of ¥5,552,217.03 in the previous period[19] - Cash flow from investment activities generated a net inflow of ¥1,187,045.07, contrasting with a net outflow of ¥5,116,248.02 in the previous period[19] - Cash and cash equivalents at the end of the period totaled ¥54,532,212.02, compared to ¥46,377,644.90 at the end of the previous period[20] - Cash and cash equivalents decreased from CNY 87,118,672.26 to CNY 56,544,816.92, a decline of approximately 35.1%[14] Assets and Liabilities - Total assets at the end of the reporting period were ¥784,307,744.04, down 3.63% from ¥813,843,574.35 at the end of the previous year[5] - Current assets decreased from CNY 256,302,322.01 to CNY 231,100,641.49, representing a reduction of about 9.8%[14] - Total liabilities decreased from CNY 277,961,889.44 to CNY 246,801,968.47, reflecting a decline of about 11.2%[15] - The equity attributable to the owners of the parent company increased slightly from CNY 535,881,684.91 to CNY 537,505,775.57, an increase of approximately 0.3%[16] - Short-term borrowings decreased from CNY 90,047,819.38 to CNY 80,013,097.16, a decline of about 11.3%[15] - The company’s long-term borrowings decreased from CNY 25,080,000.00 to CNY 22,840,000.00, a reduction of about 9.0%[15] Accounts Receivable and Prepayments - The company reported a 69.17% increase in accounts receivable, primarily due to increased credit sales during the reporting period[8] - Accounts receivable increased from CNY 28,390,203.22 to CNY 48,029,078.43, showing a significant rise of about 69.5%[14] - The company experienced a 77.23% increase in prepayments, mainly due to new clinical trial fees and financing costs incurred during the period[8] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 21,854, with the largest shareholder holding 51.15% of the shares[10] Research and Development - The company reported a significant increase in research and development expenses, totaling ¥5,344,923.89, compared to ¥7,277,255.13 in the previous period[17] Non-Operating Income - The company recorded a non-operating income of ¥763,790.51 from non-recurring gains, including asset disposal and government subsidies[6] Other Information - The company has not reported any new product launches or significant market expansions during this quarter[21]

赛隆药业集团股份有限公司董事会审计委员会 关于公司计提减值准备事项合理性的说明 根据《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管 指引第 1 号——主板上市公司规范运作》《企业会计准则》等相关法律法规的规 定，赛隆药业集团股份有限公司（以下简称"公司"）董事会审计委员会对公司 2023 年度计提减值准备事项进行了认真审议，基于审慎的判断，发表如下说明： 经审核，公司本次计提减值准备遵照并符合《企业会计准则》和公司相关 会计政策的规定，系经资产减值测试后基于谨慎性原则而做出的，依据充分。 计提资产减值准备后，公司财务报表能够更加公允地反映公司的财务状况、资 产价值及经营成果，使公司的会计信息更具有合理性，因此，我们对该事项无 异议。 特此说明。 董事会审计委员会 2024 年 4 月 18 日 （以下无正文） （本页无正文，为赛隆药业集团股份有限公司董事会审计委员会关于公司计提减 值准备事项合理性的说明签字页） 委员签字： 潘传云 唐 霖 李公奋 赛隆药业集团股份有限公司 ...

赛隆药业集团股份有限公司 关于向银行申请综合授信额度并由公司和实控 人提供担保的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 特别提示： (2)本次为资产负债率超过70%的全资子公司湖南赛隆药业（长沙）有限公司 提供的担保额度为1,000万元，敬请广大投资者注意防范风险。 证券代码：002898 证券简称：赛隆药业 公告编号：2024-031 (1)截止本公告日，公司对全资子公司担保额度为16,000万元，对参股子公 司担保额度为24,500万元，合计担保总额为40,500万元，占公司2023年度经审计 净资产的比例为75.58%；截止本公告日，公司对全资子公司实际担保金额为 6,749.87万元，对参股子公司实际担保金额为24,500万元，合计实际担保金额为 31,249.87万元，占公司2023年度经审计净资产的比例为58.31%。除上述担保外， 公司及子公司无其他担保事项，也不存在逾期担保、涉及诉讼担保的情况。 为满足公司生产经营和业务发展需要，公司及全资子公司向以下银行申请综 合授信额度： | | | | 申请授信额度 | | --- | -- ...